Guardant Health (GH) Cash & Equivalents (2017 - 2026)

Guardant Health has reported Cash & Equivalents for 10 years, with the latest figure at $1.1 billion in Q2 2026.

• Quarterly Cash & Equivalents rose 67.45% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 67.45% YoY) and the FY2025 annual result came in at $378.2 million, down 28.04% from the prior year.
• Cash & Equivalents grew to $1.1 billion in Q2 2026 per GH's latest filing, from $989.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.1 billion in Q4 2023 and troughed at $141.6 million in Q4 2022.
• A 5-year average of $587.6 million and a median of $576.8 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 80.98% in 2022, then jumped 700.25% in 2023.
• Over 5 years, Cash & Equivalents stood at $141.6 million in 2022, then soared by 700.25% to $1.1 billion in 2023, then plunged by 53.64% to $525.5 million in 2024, then declined by 28.04% to $378.2 million in 2025, then surged by 178.55% to $1.1 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.1 billion, $989.3 million, and $378.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.